Lead Product(s): AZR-MD-001
Therapeutic Area: Ophthalmology Product Name: AZR-MD-001
Highest Development Status: Phase II/ Phase III Product Type: Undisclosed
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 22, 2020
On the back of encouraging Phase 2 data to date proceeds from the funding round will be used to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of MGD.